Small-scale yet specialized BioLaurus is a compact, specialized preclinical molecular imaging provider with 2-10 employees and revenue under $1M, presenting a niche opportunity to engage agile biotech and pharma clients needing tailored imaging services without large vendor overhead.

Integrated partnerships The company emphasizes service integration with client operations, offering design, RFQ writing, outsourcing, monitoring, analysis and reporting—a compelling value prop for sponsors seeking flexible, plug‑and‑play imaging partnerships to accelerate drug discovery.

Broad modality expertise Capabilities span PET, SPECT, CT, MRI, Ultrasound, fluorescence imaging, bioluminescence and more across multiple species, enabling cross‑platform imaging studies including safety pharmacology, PK/PD and MOA—ideal for late‑stage clients needing versatile imaging consultants.

NASH and MOA focus Recent research emphasis on NASH, mu‑opioid receptor studies and platelet sequestration PK suggests targeted sell opportunities with pharma companies pursuing metabolic, CNS and hemostasis programs requiring specialized imaging readouts.

Collaborative wins Historical partnerships, such as the BTS Research collaboration and ultrasound method development for NASH in mouse models, indicate proven collaboration models and referenceable success to facilitate new business development with potential CROs and biopharma clients.